How We Do It: Administration Guide for Intralesional Immunotherapy With Talimogene Laherparepvec (T-VEC) for Advanced Melanoma

Dermatol Surg. 2020 Nov;46(11):1455-1457. doi: 10.1097/DSS.0000000000002098.

Authors

Dawn Queen¹, Faramarz H Samie², Nathalie C Zeitouni³

Affiliations

¹ Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
² Department of Dermatology, Columbia University Irving Medical Center, New York, New York.
³ Department of Dermatology, University of Arizona COM Phoenix, Phoenix, Arizona.

PMID: 31403542
DOI: 10.1097/DSS.0000000000002098

No abstract available

Publication types

Letter

MeSH terms

Biological Products / administration & dosage*
Biological Products / adverse effects
Dose-Response Relationship, Drug
Drug Administration Schedule
Herpesvirus 1, Human
Humans
Injections, Intralesional / instrumentation
Injections, Intralesional / standards*
Melanoma / diagnosis
Melanoma / pathology
Melanoma / therapy*
Neoplasm Staging / methods
Oncolytic Virotherapy / adverse effects
Oncolytic Virotherapy / instrumentation
Oncolytic Virotherapy / methods*
Oncolytic Virotherapy / standards
Patient Selection
Practice Guidelines as Topic
Skin / diagnostic imaging
Skin / pathology
Skin Neoplasms / diagnosis
Skin Neoplasms / pathology
Skin Neoplasms / therapy*
Ultrasonography, Interventional

Substances

Biological Products
talimogene laherparepvec